STOP: Broad Spectrum Antibiotics For Long COVID

> Warning: Clinical Disclaimer: This STOP page represents a hypothesis based on mechanistic evidence and should NOT replace clinical judgment. Always consult with a qualified healthcare provider before modifying any treatment plan. Evidence quality ratings reflect the strength of the mechanistic reasoning, not RCT-level clinical proof.

Conventional Rationale

Long COVID patients experiencing secondary bacterial infections are treated with broad-spectrum antibiotics as standard of care.

Why It's Counterproductive

The Long COVID microbiome is already characterized by critical depletion of SCFA-producing anaerobes — Faecalibacterium, Roseburia, and Bifidobacterium. Bernard-Raichon et al. demonstrated that COVID-associated dysbiosis drives bacterial translocation and bacteremia, creating a self-perpetuating inflammation loop Bernard Raichon2022 dysbiosis translocation bacteremia covid.

Broad-spectrum antibiotics destroy the residual protective anaerobes that remain, further collapsing the barrier against translocation. This worsens the very loop driving Long COVID persistence: dysbiosis → barrier breakdown → translocation → systemic inflammation → further dysbiosis.

Alternative Approach

  • Narrowest-spectrum antibiotic targeting the specific pathogen when antibiotics are truly necessary
  • Co-administer targeted probiotics to preserve and restore SCFA-producing communities
  • Evaluate necessity — determine if the infection truly requires systemic antibiotics vs. supportive care

Knowledge Primitive

  • Primitive 5: Two-Sided Ecological Engineering — suppressing pathogens without simultaneously restoring missing beneficial functions deepens the ecological collapse

Key Sources